ArticleACS chemical biology2019
Exploiting CD22 To Selectively Tolerize Autoantibody Producing B-Cells in Rheumatoid Arthritis.
Article in ACS chemical biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 46 citations in OpenAlex.
- Immunomodulatory Nanomaterials: Design Strategies, Mechanisms, Biomedical Applications, and Future Perspectives.Biomedicines · 2026Review
- Molecular Insights into the Engagement of High-Affinity Sialylated Ligands to Human CD22.JACS Au · 2025Article
- Biomaterial engineering strategies for B cell immunity modulations.Biomaterials science · 2024Review
- Chemical immunology: Recent advances in tool development and applications.Cell chemical biology · 2024Review
- CD22L Conjugation to Insulin Attenuates Insulin-Specific B Cell Activation.Bioconjugate chemistry · 2023Article
- Glycomimetics for the inhibition and modulation of lectins.Chemical Society reviews · 2023Review
- Impact of Siglecs on autoimmune diseases.Molecular aspects of medicine · 2023Review
- Suppressing Immune Responses Using Siglec Ligand-Decorated Anti-receptor Antibodies.Journal of the American Chemical Society · 2022Article
- Multifunctional, Multivalent PIC Polymer Scaffolds for Targeting Antigen-Specific, Autoreactive B Cells.ACS biomaterials science & engineering · 2022Article
- The interaction between nanoparticles and immune system: application in the treatment of inflammatory diseases.Journal of nanobiotechnology · 2022Review
- Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K/BxN Mice.ACS chemical biology · 2021Article
- Emerging glyco-based strategies to steer immune responses.The FEBS journal · 2021Review
- Siglec Ligands.Cells · 2021Review
- Siglec Signaling in the Tumor Microenvironment.Frontiers in immunology · 2021Review
- Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.Cellular and molecular life sciences : CMLS · 2020Review
- Coordinated roles for glycans in regulating the inhibitory function of CD22 on B cells.Biomedical journal · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease that primarily affects the synovial joints and can lead to bone erosion and cartilage damage. One hallmark of RA is anticitrullinated protein autoantibodies (ACPA) and memory citrulline-specific B-cells, which have been implicated in RA pathogenesis. While depletion of B-cells with Rituximab improves clinical responses in RA patients, this treatment strategy leaves patients susceptible to infections. Here we use of Siglec-engaging Tolerance-inducing Antigenic Liposomes (STALs) to selectively target the citrulline-specific B-cells. ACPA production from purified human RA patients' B-cells in vitro was achieved through a set of stimulation conditions, which includes the following: BAFF, anti-CD40, IL-21, and LPS. In vivo generation of citrulline specific B-cells and ACPA production was accomplished by antigenic liposomes consisting of monophosphoryl lipid A (MPLA) and a cyclic citrullinated peptide (CCP) administered to SJL/J mice. We show that STALs that codisplay a high affinity CD22 glycan ligand and synthetic citrullinated antigen (CCP STALs) can prevent ACPA production from RA patients' memory B-cells in vitro. These CCP STALs were also effective in inducing tolerance to citrullinated antigens in SJL/J mice. The results demonstrate that tolerization of the B-cells responsible for ACPA can be achieved by exploiting the inhibitory receptor CD22 with high-affinity glycan ligands. Such a treatment strategy could be beneficial in the treatment of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.